EI
TSHA icon

Ethic Inc’s Taysha Gene Therapies TSHA Stock Holding History

Ethic Inc’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$85.2K Sell
12,512
-474
-4% -$2.81K ﹤0.01% 1334
2026
Q1 		$58K Sell
12,986
-9,749
-43% -$45.3K ﹤0.01% 1215
2025
Q4 		$125K Sell
22,735
-3,049
-12% -$14.8K ﹤0.01% 1157
2025
Q3 		$84.3K Sell
25,784
-2,191
-8% -$6.2K ﹤0.01% 1157
2025
Q2 		$66.6K Buy
+27,975
New +$60.8K ﹤0.01% 1189

Other funds holding TSHA

QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
AWM
Affinity Wealth Management Wilmington, Delaware $776M AUM 43.59% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
RRA
Red Reef Advisors Boca Raton, Florida $108M AUM
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
NS
NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return

Ethic Inc's TSHA Position: Q2 2026 in Review

Ethic Inc reduced its Taysha Gene Therapies (TSHA) stake by 3.7% in Q2 2026, selling an estimated $2.81K and leaving 12,512 shares worth $85.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1334.

Ethic Inc first reported a position in TSHA in Q2 2025 and has held it in 5 quarters since. The position peaked at $125K in Q4 2025. 27 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Ethic Inc held 12,512 shares of Taysha Gene Therapies worth $85.2K as of Q2 2026.
  • Ethic Inc sold 474 Taysha Gene Therapies shares in Q2 2026, an estimated $2.81K.
  • Taysha Gene Therapies made up ﹤0.01% of Ethic Inc's portfolio in Q2 2026, its #1334 holding.
  • Ethic Inc first reported a position in Taysha Gene Therapies in Q2 2025 and has held it in 5 quarters since.
  • Ethic Inc's Taysha Gene Therapies position peaked at $125K in Q4 2025.
  • 27 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Ethic Inc's 13F filing for Q2 2026, filed 29 Jul 2026.